ATOS - Atossa Therapeutics, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

ATOS

ATOSSA THERAPEUTICS, INC.

NASDAQ

$2.42

▼ DOWN 1.63% (-0.04)

KEY STATISTICS

Market Cap$24.34 M

52w High$18.00

52w Low$1.70

Dividend Yield—

Frequency—

P/E-0.56

Volume100.78K

Shares Out.9.97M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Steven C. Quay

COMPENSATION 2026

Salary$520,000

Stock Awards$0

Incentive Plan Pay$260,000

All Other Comp.$12,000

Total$1,019,736

ABOUT

SECTOR

Healthcare

WENT PUBLIC

November 8, 2012

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$75.00

Target Low$10.00

Target Median$42.50

Target Consensus$42.50

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.—

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2026-02-02	Reverse	1:15
2018-04-20	Reverse	1:12
2016-08-26	Reverse	1:15

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

100.00%

HOLDERS

TOP 8 OF 91 · RANKED BY POSITION SIZE

Ameriprise Financial Inc

3.8M sh

$2.24M

Renaissance Technologies LLC

Millennium Management LLC

1.7M sh

$1.45M

Geode Capital Management, LLC

1.4M sh

$809.62K

Jacobs Levy Equity Management, Inc

1.0M sh

$618.49K

PRICE

$2.42 ▼ DOWN 1.63% (−$0.04)

OVERLAYS

About Atossa Therapeutics, Inc.

https://www.atossatherapeutics.com ↗

Atossa Therapeutics, Inc., a Seattle-based clinical-stage biopharmaceutical company founded in 2008, develops treatments for women's cancers, including Phase II oral (Z)-endoxifen for breast cancer, and explores immunotherapy programs.

INDUSTRY

Biotechnology

A PRODUCT ATOSSA THERAPEUTICS, INC. IS KNOWN FOR

(Z)-endoxifen

Atossa's lead clinical-stage oral drug is a potent SERM/D developed to treat and prevent breast cancer and other conditions like Duchenne Muscular Dystrophy.

COMPETITORS

COMPETITOR

Atossa Therapeutics in 2025

SENTIMENT: + POSITIVE

REGULATORY · DECEMBER 2025

Atossa Therapeutics Granted FDA Rare Pediatric Disease Designation for (Z)-Endoxifen, Sparking Investor Interest

In December 2025, the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease (RPD) designation to Atossa's lead drug candidate, (Z)-Endoxifen, for the treatment of Duchenne Muscular Dystrophy. This was a significant regulatory milestone as it opened up a new potential therapeutic area for the company's primary asset and made the drug eligible for a valuable Priority Review Voucher upon approval.

PRODUCT STRATEGY · SEPTEMBER 2025 · IN PROGRESS

Atossa Therapeutics Shifts to Accelerated Regulatory Strategy for Lead Drug (Z)-Endoxifen

In 2025, Atossa Therapeutics initiated a significant strategic shift by pursuing an accelerated regulatory pathway for its lead drug, (Z)-endoxifen, for breast cancer risk reduction. This involved engaging an internationally recognized FDA law firm and senior regulatory experts to leverage existing data and requesting a Type C meeting with the FDA to align on requirements for a New Drug Application (NDA).